Ribosomal protein S6 kinase 2 (S6K2) is a serine/threonine kinase that belongs to the family of AGC kinases, which includes PKB/Akt, PKC, PDK1, and SGK1. Mammalian cells express two isoforms of S6K, termed S6K1 and S6K2. Each of these has nuclear and cytoplasmic spicing variants, which originate from different initiation start codons. Nuclear isoforms of S6K1 and S6K2 are slightly longer, as they possess additional sequences at the Nterminus with nuclear localization signals. Biochemical and genetic studies implicated S6Ks in the regulation of cell size, growth, and energy metabolism. Deregulation of S6K signaling has been linked to various human pathologies, making them excellent targets for drug discovery. The aim of this study was to produce monoclonal antibodies directed at the Nterminal regulatory region of S6K2, which shows very low homology to S6K1 or other members of the AGC family. To achieve this goal, two S6K2 fragments covering 1-64aa and 14-64aa Nterminal sequences were expressed in bacteria as GST/6His fusion proteins. Affinity purified recombinant proteins were used as antigens for immunization, hybridoma screening, and analysis of generated clones. We produced a panel of S6K2specific antibodies, which recognized recombinant S6K2 proteins in ELISA and Western blot analysis. Further analysis of selected clones revealed that three clones, termed B1, B2, and B4, specifically recognized not only recombinant, but also endogenous S6K2 in Western blot analysis of HEK293 cell lysates. Specificity of B2 clone has been confirmed in additional commonly used immunoassays, including immunoprecipitation and immunocytochemistry. These properties make B2 MAb particularly valuable for elucidating signal transduction pathways involving S6K2 signaling under physiological conditions and in human pathologies.
Introduction
RIBOSOMAL PROTEIN S6 KINASES (S6Ks) belong to the AGC family of Ser/Thr kinases, which includes PKA, PKCs, PKB/Akt, RSK, SGK, and PDK1. There are two isoforms of S6K in mammalian cells, termed S6K1 and S6K2.
Both isoforms have cytoplasmic and nuclear splicing variants (S6K1/I and S6K2/I), which originate from alternative translation initiation sites. The 23 and 13amino acid extensions at the Ntermini of S6K1 and 2 correspondently possess nuclear localization signals (NLS) that target longer isoforms to the nucleus. In contrast to S6K1, S6K2 contains an additional NLS at the Cterminus, which determines its predominantly nuclear localization.
S6K1 and 2 share a similar modular organization in which kinase and kinase extension domains are flanked by regulatory regions with different proteinprotein interaction sequences and signaling motifs. A high level of homology is shared between S6K1 and 2 kinase and kinase extension domains (83% and 76%, respectively). However, the N and Cterminal regulatory regions of S6K1 and 2 exhibit low level of homology (38% and 12%, respectively).
A unique feature of Cterminal regulatory regions in S6Ks is the presence of autoinhibitory pseudosubstrate sequences, which resemble the carboxylterminal segment of ribosomal protein S6 (rpS6) that contains all five S6Kdirected sites of phosphorylation. The structure of S6Ks has not been solved so far, but deletion/mutational studies suggest that the acidic Nterminal sequences of S6K1/2 interact with positively charged residues in the Cterminal autoinhibitory regions, thereby keeping their kinase domains in inactive conformations. The presence of a PDZ domainbinding motif at the Cterminus of S6K1 implicates this isoform in regulating cytoskeletal rearrangements through specific interaction with the PDZ domain of the Factin binding protein neurabin. S6K2 meanwhile, contains a prolinerich region in its Cterminus that may facilitate
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Sign in to NCBI sequences of S6K1/2 interact with positively charged residues in the Cterminal autoinhibitory regions, thereby keeping their kinase domains in inactive conformations. The presence of a PDZ domainbinding motif at the Cterminus of S6K1 implicates this isoform in regulating cytoskeletal rearrangements through specific interaction with the PDZ domain of the Factin binding protein neurabin. S6K2 meanwhile, contains a prolinerich region in its Cterminus that may facilitate interaction with SH3 domain or WW domaincontaining molecules. Furthermore, the recruitment of activated S6K1 to the exon junction complex (EJC) on newly spliced mRNA was shown to be implicated in the regulation of mRNA processing via specific interaction with mRNA binding protein, Aly/REFlike target (SKAR).
The interaction of S6K1 with another mRNA binding protein, capbinding protein 80 (CBP80), has been linked to the control of the pioneer round of translation in the nucleus.
S6K2 has also been found in complexes with mRNA binding proteins, which belong to the family of heterogenous ribonucleoproteins (hnRNPs). The interaction of S6K2 with hnRNPF was shown to be required for the induction of cell proliferation.
It is well established that both S6K1 and 2 possess a prosurvival function that is mediated by different signaling mechanisms. In the case of S6K1, prosurvival signaling is linked to binding and phosphorylating MDM2 and BAD1.
In contrast, the antiapoptotic function of S6K2 was dependent upon formation of a signaling complex with BRaf and PKCɛ.
Importantly the S6K2/BRaf/PKCɛ complex has been linked to mediating chemoresistance in cancer cells.
The above studies clearly indicate that S6K1 and 2 can be found in distinct regulatory complexes located in different cellular compartments in the cytoplasm and nucleus, including endoplasmic reticulum, cytoskeleton, mitochondria and nucleolus. To date, subcellular localization and the expression of S6K isoforms in cell lines and tissues have not been adequately studied. The lack of antibodies specific to S6K1 and 2 is possibly an important contributing factor for this gap of knowledge. Taking this into account, we present in this study the production and characterization of monoclonal antibodies specific to S6K2.
Materials and Methods
Expression and affinity purification of GSTS6K2 fusion proteins cDNA fragments of human S6K2, corresponding to Nterminal sequences 1-64aa and 14-64aa, were amplified by PCR using specific oligonucleotide primers. All fragments were cloned into pET42a vector (Novagen, Madison, WI) in frame with the Nterminal GST and 6Histag sequences. Recombinant proteins designated as F1 and F2 corresponding were expressed in BL21(DE3) Escherichia coli cells. The expression of F1 and F2 fusion proteins was induced by 1 mM isopropylbD(2)thiogalactopyranoside (IPTG) for 3 h at 30°C. Affinity purification of recombinant proteins from the insoluble fractions was carried out on NiNTAagarose (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. The purity of fusion proteins was confirmed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS PAGE).
Production of hybridomas
Hybridoma production was performed according to the standard protocol.
In brief, female BALB/c mice (8 weeks old) were immunized with 20 μg of recombinant F1 protein in 50% complete Freund's adjuvant by intraperitoneal injection (i.p.). Subsequent immunizations (four in 
it was 10 after 45 days). Finally immunized mice were boosted with 15 μg of antigen by i.p. injection in PBS without adjuvant. Three days later, splenocytes from immunized mouse and SP2/0 myeloma cells cultured in RPMI 1640 medium containing 20% fetal calf serum (FCS) were fused in the presence of PEG (MW2000, Merck, Darmstadt, Germany). Positive hybrids were selected by ELISA for F1 GSTHis fusion peptide and then counterscreened against GST His alone to eliminate antiGST clones. Selected hybridoma clones were subcloned using limiting dilution method. For further characterization of generated S6K2specific antibodies, hybridoma medium or IgGs purified from ascetic fluid were used.
ELISA assays
F1, F2 recombinant proteins, or GST alone were diluted in PBS (pH 7.4) and incubated for 1 h at 37°C in 96well polystyrene plates (0.5 μg/well). To block nonspecific binding, plates were washed once with PBS containing 0.1% Tween20, and incubated with 200 μL of 2% bovine serum albumin (BSA) in PBS (pH 7.4) for 1 h at 37°C. Subsequently, plates were loaded with 100 μL aliquots of hybridoma culture media and were incubated for 1 h at 37°C. After extensive washing, 100 μL of horseradish peroxidase (HRP)-conjugated goat antimouse IgG antibodies (1:5000 v/v, Promega, Madison, WI) were added to each well and incubated at 37°C for 1 h. Plates were washed again four times, then substrate solution (0.02% H O ), 0.5 mg/mL 2,2' Azinobis(3ethylbenzothiazoline6sulfonic acid) sodium salt (SigmaAldrich, St. Louis, MO), and 0.1 M citratephosphate buffer (pH 5.8) were added to each well. After 15 min incubation at 37°C, the light absorbance of the each well was determined at 490 nm.
Production and purification of monoclonal antibodies from mouse ascites
BALB/c mice were injected with 0.5 mL of pristane and 7-10 days later inoculated with 5×10 hybridoma cells. The ascitic fluid was collected after 10-14 days. The fraction of immunoglobulins was precipitated from ascitic fluid with 50% ammonium sulphate and used for affinity purification by Protein GSepharose CL4B (GE Healthcare, Piscataway, NJ) chromatography. The IgG fractions were pulled together and dialyzed in a phosphatebuffered saline (PBS, pH 7.4). The aliquots of purified antibodies were stored at −70°C.
Western blot analysis
Cell lysates were prepared using lysis buffer containing 20 mM TrisHCl (pH 7.5), 150 mM NaCl, 1% Triton X100, 50 mM NaF, 5 mM EDTA, and a mixture of protease inhibitors (Roche Molecular Diagnostics, Meylan, France). Cell lysates (30 μg) were separated by SDSPAGE and transferred onto ImmobilonP membrane (Millipore, Billerica, MA). The membrane was blocked with 5% skim milk in TBST (50 mM TrisHCl [pH 7.4], 150 mM NaCl, and 0.05% Tween20) for 1 h at RT, and then incubated with culture media of positive clones for 1 h at RT. After washing three times with TBST, HRPconjugated goat antimouse IgG in 1:6000 dilution (Promega) were incubated with the membrane for 1 h at RT. Finally, the membrane was developed using an ECL kit (GE Healthcare) and then exposed to Agfa Xray film.
Immunoprecipitation
One μg of MAbs purified from ascites was incubated with 15 μL of 50% slurry of protein G Sepharose (GE Healthcare) and 500 μg of cell extract in a total volume of 500 μL lysis buffer and rotated at 4°C for 3 h. Immune complexes bound to Protein G Sepharose beads were recovered by brief centrifugation and washed three times with 1 mL of lysis buffer. Finally samples were boiled for 5 min in Laemmli sample buffer, separated by SDSPAGE and immunoblotted with corresponding antibodies. As a control, we used Protein G Sepharose beads incubated with monoclonal antibodies or cell lysates alone.
Immunocytochemistry
Immunocytochemical staining was performed according to the basic protocol as described previously.
In brief, human embryonic kidney (HEK) 293 cells were grown on a 6well plate in complete DMEM medium with 10% FCS until they reached 80-90% confluence. Then, cells were fixed with methanol (1 mL of ice cold methanol/well) at −20°C for 10 min. After washing three times with 0.5% BSA in PBS (pH 7.4), fixed cells were incubated with purified antiS6K2 monoclonal antibody (clone B2) at a final concentration of 2 μg/mL at 4°C for 12 h. After washing three times with 0.5% BSA in PBS (pH 7.4), secondary HRPconjugated goat anti mouse IgG (1:500, Promega) was added and incubated with cells for 2 h at RT. The staining was three times with 0.5% BSA in PBS (pH 7
Results and Discussion
The aim of this study was to produce monoclonal antibodies directed at the Nterminal regulatory region of S6K2/I and S6K2/II, which shows very low homology to S6K1 or other members of the AGC family.
S6K2 MAb production
cDNA fragments of S6K2 coding for Nterminal 1-64 aa and 14-64aa sequences were cloned into pET42a vector, expressed in E. coli, and recombinant proteins (F1 and F2 correspondently) were purified as recommended by the manufacturer using NiNTAagarose (  Fig. 1A, B) . Peptide F1 covering NLS located within the 1-13 aa sequence of S6K2/I was used as an antigen for immunization. We maintained the standard scheme of immunization, boosting animals every 2 weeks. The titer of antiS6K2 antibodies in the serum of immunized mice was nearly 10 on the 45th day of immunization. Spleen cells from one of the immunized mice were then fused with SP2/0 myeloma cells. The resulting hybridoma cells were selected in HAT medium and tested for the production of anti S6K2 antibodies on the tenth day after fusion. Screening of ten 96well plates with growing hybrids by ELISA using S6K2 recombinant peptide F1 as antigens allowed us to identify 15 positive clones. We used recombinant GSTHis protein as an antigen in the second round of ELISA screening in order to detect clones producing antibodies specific to GSTHis. Only four from 15 selected primary clones were negative towards GST/His. ELISA screening of these clones with S6K2 recombinant peptides F1 and F2 demonstrated positive response for both peptides, indicating that none of the clones was specific to NLS region (1-13 aa) of S6K2 and the epitopes for all four clones were located within the 14-64 aa sequence of S6K2 (Fig. 1C) . The summary of ELISA screening of hybrid cells is presented in Table 1 . Table 1 .
Selection of Hybridoma Cell Lines Expressing AntiS6K2 MAbs
Next we examined the specificity of selected hybridoma clones in Western blotting using recombinant S6K2 proteins (F1 and F2) . The obtained data show that MAbs from four ELISA selected clones specifically recognized both recombinant peptides (Fig. 1D) .
Application of antiS6K2 MAbs in Western blot analysis with total cell lysates
To further analyze antibodies, we tested all selected clones in Western blotting with HEK293 cell lysates ( Fig. 2A) . Only MAbs from three selected clones (B1, B2, and B4) could recognize endogenous S6K2 with similar specificity. As a positive control, we used antiS6K2/Cterm rabbit polyclonal antibodies that were characterized and applied in previous studies. These results clearly show that antibodies produced by B1, B2, and B4 clones specifically recognize endogenous S6K2, albeit with different specificity. B4 MAbs could recognize an additional 60 kDa band that may represent nonspecific binding. Taking into account that as antigen for immunization and hybridoma screening we used human S6K2 peptides, in the next stage we analyzed the cross reactivity of generated MAbs with S6K2 from other mammals. For further experiments we chose the B2 clone. Western blot analysis of cell lysates from cell lines of different origin showed the crossreactivity of MAbs produced by B2 clone with S6K2 from mouse, rat, and human (Fig. 2B) . B2 MAb detected endogenous S6K2 in all cell lysates analyzed. However, in contrast to antiS6K2/Cterm polyclonal antibodies, B2 MAbs detected additional protein bands in rat and mouse cells (  Fig. 2B ) that may represent isoforms of S6K2 lacking of Cterminal sequence.
Application of antiS6K2 (2B) MAbs for immunoprecipitation
To broaden the application of generated antibody, we tested B2 MAbs in immunoprecipitation of endogenous S6K2. For this purpose we used HEK 293 cell lysates. The data (Fig. 3A) 
Application of antiS6K2 MAbs for cytochemistry
Finally MAbs produced by clone B2 were used in immunocytochemistry. HEK293 cells were grown and fixed as described in the section on Materials and Methods. AntiS6K2 (B2) MAbs produced strong DAB staining (right panel) in comparison to the control (left panel) of secondary antibodies (Fig. 3B) . Our data suggest that in HEK293, S6K2 was predominantly detected in cell cytoplasm. These data correlate with our previous observation in which S6K2 was detected predominantly in the cytoplasm of thyroid follicle cells; however, in the monolayer culture of thyrocytes in the course of follicles outspreading, S6K2 have been observed in nuclei as well.
Taken together, this study describes the production of antiS6K2 monoclonal antibodies (clone B2), which are suitable for various immunoassays, including ELISA, Western blot analysis, immunprecipitation, and immunocytochemistry. The produced antibodies provide a very useful tool to study the function of S6K2 and its possible isoforms in different macromolecular complexes.
